(Q36139277)

12 August 2017

1 reference

title

Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis (English)

1 reference

Katherine A Lyseng-Williamson

12 August 2017

0 references

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

12 August 2017

David Murdoch

1

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

65

1 reference

12 August 2017

9

1 reference

12 August 2017

1295-1312

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565090-00010

12 August 2017

0 references

cites work

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously

1 reference

12 December 2020

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

The expression of microfilament-associated cell-cell contacts in brain endothelial cells is modified by IFN-beta1a (Rebif).

1 reference

12 December 2020

Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers

1 reference

12 December 2020

1 reference

12 December 2020

International consensus statement on the use of disease-modifying agents in multiple sclerosis

1 reference

12 December 2020

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

1 reference

12 December 2020

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

Immunogenicity of interferon beta: differences among products

1 reference

12 December 2020

Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes

1 reference

12 December 2020

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers

1 reference

12 December 2020

Drug treatment of multiple sclerosis

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

A comparative study of the relative bioavailability of different interferon beta preparations

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta

1 reference

12 December 2020

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

12 December 2020

Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis

1 reference

12 December 2020

Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Disease-modifying Therapies for Multiple Sclerosis.

1 reference

12 December 2020

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial

1 reference

12 December 2020

Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

1 reference

12 December 2020

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

1 reference

12 December 2020

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

1 reference

12 December 2020

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis

1 reference

12 December 2020

Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review

1 reference

12 December 2020

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

12 December 2020

Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis

1 reference

12 December 2020

Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients

1 reference

12 December 2020

Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS.

1 reference

12 December 2020

Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

1 reference

12 December 2020

10.2165/00003495-200565090-00010

Identifiers

DOI

1 reference

PubMed ID

15916455

Dimensions Publication ID

12 August 2017

0 references

1 reference

PubMed ID

15916455